STOCK TITAN

Oramed (NASDAQ: ORMP) CSO uses 435,084 shares to cover RSU tax

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ORAMED PHARMACEUTICALS INC. Chief Scientific Officer Miriam Kidron reported a tax-related share disposition tied to equity compensation. A total of 435,084 shares of common stock were used to satisfy tax withholding obligations from the vesting and settlement of Restricted Stock Units. These shares were valued at $3.31 per share, based on the closing price immediately before the vesting date. Following this tax-withholding disposition, Kidron directly holds 1,133,138 shares of Oramed common stock.

Positive

  • None.

Negative

  • None.
Insider Kidron Miriam
Role Chief Scientific Officer
Type Security Shares Price Value
Tax Withholding Common Stock 435,084 $3.31 $1.44M
Holdings After Transaction: Common Stock — 1,133,138 shares (Direct)
Footnotes (1)
  1. [object Object]
Tax-withholding shares 435,084 shares Common stock used to satisfy tax withholding obligations
Valuation price $3.31 per share Closing price immediately before RSU vesting date
Shares held after transaction 1,133,138 shares Direct common stock holdings following the reported disposition
Restricted Stock Units financial
"attributable to the vesting and settlement of Restricted Stock Units, which were valued"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"used to satisfy tax withholding obligations attributable to the vesting and settlement"
closing price financial
"valued at the closing price of the Issuer's Common Stock on the date immediately prior"
Common Stock financial
"Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kidron Miriam

(Last)(First)(Middle)
1185 AVENUE OF THE AMERICAS
THIRD FLOOR

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/30/2026F435,084(1)D$3.31(1)1,133,138D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.
/s/ Miriam Kidron03/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ORMP executive Miriam Kidron report on this Form 4?

Miriam Kidron reported a tax-withholding disposition of 435,084 Oramed common shares. The shares were used to cover tax obligations from vesting Restricted Stock Units and were not an open-market sale, according to the transaction code and footnote description.

How many ORMP shares were used for tax withholding by Miriam Kidron?

Miriam Kidron used 435,084 Oramed common shares to satisfy tax withholding obligations. The filing notes these shares related to the vesting and settlement of Restricted Stock Units and were valued at the prior day’s closing price of $3.31 per share.

At what price were the ORMP shares valued for Miriam Kidron’s tax withholding?

The shares used for tax withholding were valued at $3.31 per share. The footnote states this reflects the closing price of Oramed’s common stock on the trading day immediately preceding the vesting date of the Restricted Stock Units.

How many ORMP shares does Miriam Kidron hold after this Form 4 transaction?

After the tax-withholding disposition, Miriam Kidron directly holds 1,133,138 Oramed common shares. This post-transaction balance is disclosed in the Form 4 as the total number of common stock shares owned following the reported event.

Was Miriam Kidron’s ORMP Form 4 transaction an open-market sale of shares?

The Form 4 characterizes the transaction as a tax-withholding disposition, not an open-market sale. Shares were delivered to satisfy tax obligations from Restricted Stock Unit vesting, consistent with the F transaction code and explanatory footnote in the filing.